ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0005010

coronary artery disorder

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. coronary artery disorder. Diseases, record MONDO_0005010. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005010

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
coronary artery disorder
Open Targets
Open Targets ID
MONDO_0005010
Open Targets
Other names
Arterioscleroses, Coronary, Arteriosclerosis, Coronary, Artery Disease, Coronary, Artery Diseases, Coronary, Atheroscleroses, Coronary, Atherosclerosis, Coronary, CAD, CHD, CHD (coronary heart disease), CORONARY ARTERY DIS, CORONARY DIS, CORONARY HEART DIS, Coronary Arterioscleroses, Coronary Arteriosclerosis, Coronary Artery Diseases, Coronary Atheroscleroses, Coronary Atherosclerosis, Coronary Diseases, Coronary Heart Diseases, Disease, Coronary, Disease, Coronary Artery, Disease, Coronary Heart, Diseases, Coronary, Diseases, Coronary Artery, Diseases, Coronary Heart, Heart Disease, Coronary, Heart Diseases, Coronary, coronary artery disease, coronary artery disease or disorder, coronary disease, coronary heart disease, disease of coronary artery, disease or disorder of coronary artery, disorder of coronary artery
Open Targets
Disease Ontology
DOID:3393
Disease Ontology
MeSH
D003324
MeSH
NCI Thesaurus
C26732
NCI Thesaurus
Highest stage of its drugs
Approval, for 30 of its 241 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD
Open Targets

Drugs241

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
ASPIRINCHEMBL25Small moleculeApprovalDailyMed393838Drugs and targets
TICAGRELORCHEMBL398435Small moleculeApprovalDailyMed and PMDA343232Drugs and targets
SIMVASTATINCHEMBL1064Small moleculeApprovalDailyMed1161111Drugs and targets
NIACINCHEMBL573Small moleculeApprovalDailyMed251010Drugs and targets
COLCHICINECHEMBL107Small moleculeApprovalClinicalTrials.gov, at phase 4111010Drugs and targets
EVOLOCUMABCHEMBL2364655AntibodyApprovalDailyMed1099Drugs and targets
RIVAROXABANCHEMBL198362Small moleculeApprovalEMA Human Drugs977Drugs and targets
NITROGLYCERINCHEMBL730Small moleculeApprovalDailyMed5355Drugs and targets
ALIROCUMABCHEMBL2109540AntibodyApprovalDailyMed433Drugs and targets
LOVASTATINCHEMBL503Small moleculeApprovalDailyMed522Drugs and targets

1 to 10 of 241

See all 241 drugs

Targets273

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
HMGCR3-hydroxy-3-methylglutaryl-coenzyme A reductase9HMG-CoA reductase inhibitorApprovalhttps://conductscience.org/library/genes/3156Drugs and targets
ADRB1Adrenergic receptor8Adrenergic receptor agonist; Adrenergic receptor beta antagonist; Beta-1 adrenergic receptor antagonistPhase 3https://conductscience.org/library/genes/153Drugs and targets
GUCY1A1Soluble guanylate cyclase7Soluble guanylate cyclase activator; Soluble guanylate cyclase positive allosteric modulatorApprovalhttps://conductscience.org/library/genes/2982Drugs and targets
GUCY1A2Soluble guanylate cyclase7Soluble guanylate cyclase activator; Soluble guanylate cyclase positive allosteric modulatorApprovalhttps://conductscience.org/library/genes/2977Drugs and targets
GUCY1B1Soluble guanylate cyclase7Soluble guanylate cyclase activator; Soluble guanylate cyclase positive allosteric modulatorApprovalhttps://conductscience.org/library/genes/2983Drugs and targets
ACEAngiotensin-converting enzyme5Angiotensin-converting enzyme inhibitorApprovalhttps://conductscience.org/library/genes/1636Drugs and targets
AGTR1Type-1 angiotensin II receptor5Type-1 angiotensin II receptor antagonistPhase 3https://conductscience.org/library/genes/185Drugs and targets
GABRA1GABA-A receptor; anion channel5GABA-A receptor; anion channel positive allosteric modulatorPhase 2https://conductscience.org/library/genes/2554Drugs and targets
GABRA2GABA-A receptor; anion channel5GABA-A receptor; anion channel positive allosteric modulatorPhase 2https://conductscience.org/library/genes/2555Drugs and targets
GABRA3GABA-A receptor; anion channel5GABA-A receptor; anion channel positive allosteric modulatorPhase 2https://conductscience.org/library/genes/2556Drugs and targets

1 to 10 of 273

See all 273 targets

Trials340

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 8 more are not shown, since the checks do not confirm them.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT03381742Efficacy and Safety of Low-dose TicagrelorPhase 2/33,0432019-09-30Coronary Artery DiseaseCLOPIDOGREL, TICAGRELORIts record names the diseaseClinicalTrials.gov
NCT00006305Bypass Angioplasty Revascularization Investigation in Type 2 DiabetesPhase 32,3682011-05-12Coronary Disease, Cardiovascular Diseases, Heart Diseases, Insulin Resistance, Diabetes Mellitus, Diabetes Mellitus, Non-Insulin-DependentINSULIN HUMAN, METFORMIN, ROSIGLITAZONEIts record names the diseaseClinicalTrials.gov
NCT00620542CRESTOR Athero Imaging Head to Head IVUS StudyPhase 32,3332012-06-25Coronary AtherosclerosisATORVASTATIN, ROSUVASTATINIts record names the diseaseClinicalTrials.gov
NCT03730116Assessment of the Efficacy and Tolerability of the Fixed-dose Combination of Bisoprolol/Perindopril1,9092020-12-23Arterial Hypertension, CHD - Coronary Heart DiseaseBISOPROLOL, PERINDOPRILIts record names the diseaseClinicalTrials.gov
NCT0052582412-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With EzetimibePhase 31,7432009-10-07Hypercholesterolemia, Coronary Heart Disease, AtherosclerosisEZETIMIBE, ROSUVASTATIN, SIMVASTATINIts record names the diseaseClinicalTrials.gov
NCT00044213Trial to Assess Chelation Therapy (TACT)Phase 31,7082013-11-05Coronary Artery DiseaseEDETIC ACIDIts record names the diseaseClinicalTrials.gov
NCT01381679Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Levels in Participants With Coronary Heart Disease (CHD) Already Treated With a Statin (MK-0653A-205 AM1)1,6822012-03-22HypercholesterolemiaEZETIMIBEIts record names the diseaseClinicalTrials.gov
NCT00535405
A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)
Phase 31,2892010-05-25HypercholesterolemiaEZETIMIBE, SIMVASTATINIts record names the diseaseClinicalTrials.gov
NCT00409773Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)Phase 31,1432009-08-04Hypercholesterolemia, Metabolic SyndromeEZETIMIBE, SIMVASTATINIts record names the diseaseClinicalTrials.gov
NCT01515345Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI RegistryPhase 31,0082013-05-01Platelet Inhibition, Coronary Stent ImplantationCLOPIDOGREL, PRASUGREL, TICAGRELORIts record names the diseaseClinicalTrials.gov

1 to 10 of 340

See all 340 trials

Comparisons in its trials79

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Rosuvastatin 40 mg vs Atorvastatin 80 mg: Numbers of Patients Showing Regression in TAV371 of 520336 of 5191,039NCT00620542Trial comparisons
Rosuvastatin 40 mg vs Atorvastatin 80 mg: Numbers of Patients Showing Regression in PAV356 of 520328 of 5191,039NCT00620542Trial comparisons
Standard Therapy vs Individualized Therapy: Any Bleeding Event17 of 6649 of 3431,007NCT01515345Trial comparisons
Standard Therapy vs Individualized Therapy: Probable Stent Thrombosis2 of 6640 of 3431,007NCT01515345Trial comparisons
Standard Therapy vs Individualized Therapy: Definite Stent Thrombosis1 of 6640 of 3431,007NCT01515345Trial comparisons
Standard Therapy vs Individualized Therapy: serious adverse events26 of 66418 of 3431,007NCT01515345Trial comparisons
Evolocumab vs Placebo: serious adverse events135 of 484142 of 484968NCT01813422Trial comparisons
Dalcetrapib vs Placebo: serious adverse events61 of 47463 of 462936NCT01059682Trial comparisons
Aliskiren 300 mg vs Placebo: serious adverse events76 of 30597 of 308613NCT00853827Trial comparisons
Dalcetrapib vs Placebo: deaths from any cause0 of 2361 of 236472NCT00655538Trial comparisons

1 to 10 of 79

See all 79 comparisons in its trials

Papers from its trials388

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
40375481RESULT1PubMed
34010616RESULT1PubMed
33171520RESULT1PubMed
33028101RESULT1PubMed
29622563RESULT1PubMed
29301785RESULT1PubMed
29045581RESULT1PubMed
28844193RESULT1PubMed
28279371RESULT1PubMed
28186222RESULT1PubMed

1 to 10 of 388

See all 388 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005010

GET https://conductscience.org/api/diseases/v1/MONDO_0005010/drugs?page=2

API referenceFor AI assistants